Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Given Average Rating of “Buy” by Brokerages

Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) have been assigned an average recommendation of “Buy” from the twenty-two ratings firms that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a hold recommendation, twenty have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $181.33.

Several equities analysts have recently issued reports on SRPT shares. Evercore ISI decreased their price target on Sarepta Therapeutics from $179.00 to $170.00 and set an “outperform” rating on the stock in a research note on Thursday, November 7th. Piper Sandler lowered their target price on Sarepta Therapeutics from $205.00 to $200.00 and set an “overweight” rating for the company in a research note on Thursday, August 8th. Jefferies Financial Group initiated coverage on shares of Sarepta Therapeutics in a research note on Monday, October 21st. They issued a “buy” rating and a $165.00 price target on the stock. Cantor Fitzgerald upgraded shares of Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and upped their price objective for the stock from $152.00 to $167.00 in a research report on Thursday, November 7th. Finally, Robert W. Baird cut their target price on shares of Sarepta Therapeutics from $200.00 to $193.00 and set an “outperform” rating on the stock in a research report on Thursday, November 7th.

Insider Buying and Selling

In related news, CFO Ian Michael Estepan sold 5,985 shares of the company’s stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $137.36, for a total transaction of $822,099.60. Following the sale, the chief financial officer now owns 33,946 shares in the company, valued at $4,662,822.56. This represents a 14.99 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 7.70% of the stock is owned by insiders.

Hedge Funds Weigh In On Sarepta Therapeutics

Several institutional investors have recently added to or reduced their stakes in the business. Fifth Third Wealth Advisors LLC acquired a new position in shares of Sarepta Therapeutics during the 2nd quarter valued at $607,000. Teachers Retirement System of The State of Kentucky acquired a new position in shares of Sarepta Therapeutics during the second quarter valued at about $4,771,000. Simplify Asset Management Inc. boosted its position in shares of Sarepta Therapeutics by 84.6% during the 3rd quarter. Simplify Asset Management Inc. now owns 193,010 shares of the biotechnology company’s stock worth $24,105,000 after purchasing an additional 88,474 shares in the last quarter. Securian Asset Management Inc. acquired a new stake in shares of Sarepta Therapeutics in the 2nd quarter valued at about $1,187,000. Finally, Natixis Advisors LLC bought a new stake in Sarepta Therapeutics in the 2nd quarter valued at about $1,918,000. 86.68% of the stock is owned by institutional investors and hedge funds.

Sarepta Therapeutics Stock Performance

Shares of NASDAQ:SRPT opened at $104.54 on Tuesday. Sarepta Therapeutics has a 1 year low of $78.67 and a 1 year high of $173.25. The stock has a market capitalization of $9.99 billion, a price-to-earnings ratio of 83.63 and a beta of 0.81. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03. The company’s 50 day simple moving average is $123.72 and its 200 day simple moving average is $132.36.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.